CL2013001943A1 - Uso de un agonista opioide y un antagonista opioide para preparar una forma farmaceutica para el tratamiento de la enfermedad de parkinson y/o al menos un sintoma de la misma. - Google Patents

Uso de un agonista opioide y un antagonista opioide para preparar una forma farmaceutica para el tratamiento de la enfermedad de parkinson y/o al menos un sintoma de la misma.

Info

Publication number: CL2013001943A1
Authority: CL; Chile
Prior art keywords: opioid; parkinson; symptom; disease; prepare
Prior art date: 2010-12-28

Application number

CL2013001943A

Other languages

English (en)

Inventor

Michael Hopp

Claudia Trenkwalder

Original Assignee

Euro Celtique Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-28

Filing date

2013-06-28

Publication date

2013-11-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43903970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013001943(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-06-28 Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa

2013-11-29 Publication of CL2013001943A1 publication Critical patent/CL2013001943A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Gynecology & Obstetrics (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Inorganic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CL2013001943A 2010-12-28 2013-06-28 Uso de un agonista opioide y un antagonista opioide para preparar una forma farmaceutica para el tratamiento de la enfermedad de parkinson y/o al menos un sintoma de la misma. CL2013001943A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP10197210		2010-12-28

Publications (1)

Publication Number	Publication Date
CL2013001943A1 true CL2013001943A1 (es)	2013-11-29

Family

ID=43903970

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013001943A CL2013001943A1 (es)	2010-12-28	2013-06-28	Uso de un agonista opioide y un antagonista opioide para preparar una forma farmaceutica para el tratamiento de la enfermedad de parkinson y/o al menos un sintoma de la misma.

Country Status (20)

Country	Link
US (1)	US20140037729A1 (es)
EP (1)	EP2658523A1 (es)
JP (2)	JP5864606B2 (es)
KR (2)	KR101632858B1 (es)
CN (1)	CN103347495B (es)
AR (1)	AR084620A1 (es)
AU (1)	AU2011351447B2 (es)
BR (1)	BR112013016862A2 (es)
CA (1)	CA2822528C (es)
CL (1)	CL2013001943A1 (es)
EA (1)	EA025747B1 (es)
MX (1)	MX354125B (es)
MY (1)	MY162895A (es)
NZ (1)	NZ612837A (es)
PH (1)	PH12013501244A1 (es)
SG (1)	SG191208A1 (es)
TW (2)	TW201628618A (es)
UA (1)	UA109301C2 (es)
WO (1)	WO2012089738A1 (es)
ZA (1)	ZA201304303B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX344846B (es)	2010-05-10	2017-01-10	Euro-Celtique S A *	Combinacion de granulos cargados activos con activos adicionales.
US9993433B2 (en)	2010-05-10	2018-06-12	Euro-Celtique S.A.	Manufacturing of active-free granules and tablets comprising the same
MY162895A (en) *	2010-12-28	2017-07-31	Euro Celtique Sa	A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
US10736889B2 (en)	2011-04-29	2020-08-11	Rutgers, The State University Of New Jersey	Method of treating dyskinesia
PL2701707T3 (pl) *	2011-04-29	2021-03-08	Rutgers, The State University Of New Jersey	Sposób leczenia dyskinezji
US9918980B2 (en)	2011-04-29	2018-03-20	Rutgers, The State University Of New Jersey	Method of treating dyskinesia
WO2014004126A1 (en)	2012-06-26	2014-01-03	Fleming C Andrew	Treating postoperative nausea and vomiting
WO2015011189A1 (en) *	2013-07-23	2015-01-29	Euro-Celtique S.A.	A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
EP3068397A1 (en) *	2013-11-13	2016-09-21	Euro-Celtique S.A.	Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
CA2847781C (en) *	2014-03-28	2019-03-12	Purdue Pharma	Reducing drug liking in a subject
US20150352099A1 (en) *	2014-06-04	2015-12-10	Mentinova Inc.	Compositions and Methods of Reducing Sedation
WO2016029218A1 (en)	2014-08-22	2016-02-25	The Arizona Board Of Regents On Behalf Of The University Of Arizona	Substituted 1-arylethyl-4-acylaminopiperidine derivatives as opioid/alpha-adrenoreceptor modulators and method of their preparation
WO2016116615A1 (en) *	2015-01-23	2016-07-28	Euro-Celtique S.A.	A combination of hydromorphone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US20160256451A1 (en) *	2015-03-06	2016-09-08	Develco Pharma Schweiz Ag	Dosage of naloxone
WO2016190766A1 (en) *	2015-05-26	2016-12-01	Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa	Compositions for use in treating parkinson's disease and related disorders
US20180104236A1 (en) *	2016-09-26	2018-04-19	Euro-Celtique S. A.	Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
JP7535569B2 (ja) *	2019-08-11	2024-08-16	カッパ－ファーマ・リミテッド・ライアビリティ・カンパニー	オピオイドヘキサジエノエート及び選択的に置換されたヘキサジエノエートによってオピオイド受容体の結合を改善する組成物並びに方法
US20230343429A1 (en) *	2019-10-31	2023-10-26	The United States Government As Represented By The Department Of Veterans Affairs	Methods, systems, and apparatus for tapering or uptitrating drug dosages
AU2021206252A1 (en)	2020-01-10	2022-07-28	Trevi Therapeutics, Inc.	Methods of administering nalbuphine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4769372A (en) *	1986-06-18	1988-09-06	The Rockefeller University	Method of treating patients suffering from chronic pain or chronic cough
GEP20053614B (en) *	2000-02-08	2005-09-26	Euro Celtique Sa	Compositions for Oral Administration Containing Opioid Agonist
WO2002005647A1 (en) *	2000-07-13	2002-01-24	Euro-Celtique, S.A.	Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics
JP4256259B2 (ja) *	2001-07-18	2009-04-22	ユーロ−セルティークエス．エイ．	オキシコドン及びナロキソンの医薬配合物
US20060177381A1 (en) *	2002-02-15	2006-08-10	Howard Brooks-Korn	Opiopathies
EP1604666A1 (en) *	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1695700A1 (en) *	2005-02-28	2006-08-30	Euro-Celtique S.A.	Dosage form containing oxycodone and naloxone
US20070232638A1 (en) *	2006-04-03	2007-10-04	Howard Brooks-Korn	Opiopathies
WO2009132313A2 (en) *	2008-04-25	2009-10-29	Progenics Pharmaceuticals, Inc.	Morphinan derivatives of organic and inorganic acids
PT2317991T (pt) *	2008-07-07	2017-08-03	Euro Celtique Sa	Utilização de antagonistas de opióides para tratar a retenção urinária
RS58240B1 (sr) *	2009-03-10	2019-03-29	Euro Celtique Sa	Farmaceutske kombinacije sa trenutnim oslobađanjem koje obuhvataju oksikodon i nalokson
GB0909680D0 (en) *	2009-06-05	2009-07-22	Euro Celtique Sa	Dosage form
MY162895A (en) *	2010-12-28	2017-07-31	Euro Celtique Sa	A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease

2011
- 2011-12-27 MY MYPI2013002299A patent/MY162895A/en unknown
- 2011-12-27 KR KR1020157016070A patent/KR101632858B1/ko not_active Expired - Fee Related
- 2011-12-27 BR BR112013016862A patent/BR112013016862A2/pt not_active Application Discontinuation
- 2011-12-27 CA CA2822528A patent/CA2822528C/en not_active Expired - Fee Related
- 2011-12-27 SG SG2013046610A patent/SG191208A1/en unknown
- 2011-12-27 NZ NZ612837A patent/NZ612837A/en not_active IP Right Cessation
- 2011-12-27 JP JP2013546698A patent/JP5864606B2/ja not_active Expired - Fee Related
- 2011-12-27 EA EA201390977A patent/EA025747B1/ru not_active IP Right Cessation
- 2011-12-27 TW TW105112827A patent/TW201628618A/zh unknown
- 2011-12-27 MX MX2013007622A patent/MX354125B/es active IP Right Grant
- 2011-12-27 US US13/976,912 patent/US20140037729A1/en not_active Abandoned
- 2011-12-27 TW TW100148974A patent/TWI554271B/zh not_active IP Right Cessation
- 2011-12-27 WO PCT/EP2011/074103 patent/WO2012089738A1/en not_active Ceased
- 2011-12-27 AU AU2011351447A patent/AU2011351447B2/en not_active Ceased
- 2011-12-27 CN CN201180063522.0A patent/CN103347495B/zh not_active Expired - Fee Related
- 2011-12-27 UA UAA201309397A patent/UA109301C2/uk unknown
- 2011-12-27 EP EP11802440.5A patent/EP2658523A1/en not_active Withdrawn
- 2011-12-27 KR KR1020137019870A patent/KR101618929B1/ko not_active Expired - Fee Related
- 2011-12-27 AR ARP110104969A patent/AR084620A1/es unknown
- 2011-12-27 PH PH1/2013/501244A patent/PH12013501244A1/en unknown
2013
- 2013-06-12 ZA ZA2013/04303A patent/ZA201304303B/en unknown
- 2013-06-28 CL CL2013001943A patent/CL2013001943A1/es unknown
2015
- 2015-09-18 JP JP2015184577A patent/JP6074003B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2016040268A (ja)	2016-03-24
EA025747B1 (ru)	2017-01-30
SG191208A1 (en)	2013-07-31
JP5864606B2 (ja)	2016-02-17
KR20150076262A (ko)	2015-07-06
JP6074003B2 (ja)	2017-02-01
TW201302199A (zh)	2013-01-16
TWI554271B (zh)	2016-10-21
NZ612837A (en)	2014-11-28
KR101632858B1 (ko)	2016-06-22
WO2012089738A1 (en)	2012-07-05
EA201390977A1 (ru)	2013-12-30
AR084620A1 (es)	2013-05-29
CN103347495B (zh)	2017-06-20
MX2013007622A (es)	2013-12-06
UA109301C2 (uk)	2015-08-10
MY162895A (en)	2017-07-31
AU2011351447A1 (en)	2013-07-25
EP2658523A1 (en)	2013-11-06
PH12013501244A1 (en)	2013-07-15
TW201628618A (zh)	2016-08-16
JP2014501268A (ja)	2014-01-20
CA2822528A1 (en)	2012-07-05
ZA201304303B (en)	2014-02-26
CA2822528C (en)	2017-07-18
KR20130106431A (ko)	2013-09-27
CN103347495A (zh)	2013-10-09
US20140037729A1 (en)	2014-02-06
AU2011351447B2 (en)	2016-02-25
BR112013016862A2 (pt)	2016-10-04
KR101618929B1 (ko)	2016-05-09
MX354125B (es)	2018-02-14

Publication	Publication Date	Title
CL2013001943A1 (es)	2013-11-29	Uso de un agonista opioide y un antagonista opioide para preparar una forma farmaceutica para el tratamiento de la enfermedad de parkinson y/o al menos un sintoma de la misma.
NO2020018I1 (no)	2020-06-17	Darolutamide, optionally in the form of a pharmaceutically acceptable salt or ester thereof
BR112014010206A2 (pt)	2017-05-16	composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
JP2011006431A5 (es)	2011-09-15
EP2475427A4 (en)	2013-06-26	ACTRIIB ANTAGONISTS, THEIR DOSAGE AND APPLICATIONS THEREOF
CO6950467A2 (es)	2014-05-20	Forma de dosificación farmacéutica oral resistente a alteración comprendiendo agonista opioide y antagonista opioide
BRPI1012004A2 (pt)	2016-05-10	"forma farmacêutica"
BR112013023174A2 (pt)	2016-08-09	"compostos derivados de triterpenoide de c4-monometila, composição farmacêutica compreendendo os referidos compostos e uso dos mesmos"
BRPI0906467A2 (pt)	2016-04-26	forma de dose farmacêutica
IL211279A (en)	2015-03-31	Use of the tspan12 antagonist in the preparation of a blood vessel inhibition drug
BR112014010177A2 (pt)	2017-04-25	composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BRPI0918502A2 (pt)	2015-12-01	aminoindanos substituídos e análogos dos mesmos, e o uso farmacêutico dos mesmos
HRP20160579T1 (hr)	2016-07-29	Spoj indola i njegova farmaceutska upotreba
BRPI0917540A2 (pt)	2015-11-17	composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável
IL223783B (en)	2018-06-28	Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
DK2399580T3 (da)	2013-06-24	Farmaceutiske doseringsformer
BRPI1012116A2 (pt)	2016-03-15	composição farmacêutica para o tratamento de doenças cardíacas
BRPI1009392A2 (pt)	2016-03-08	"formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
CL2013003372A1 (es)	2014-07-25	Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
MX354249B (es)	2018-02-20	Formas de dosificación farmacéuticas intranasales que comprenden naloxona.
IT1403847B1 (it)	2013-11-08	Composizioni farmaceutiche comprendenti rifaximina e loro uso.
BRPI1013988A2 (pt)	2016-04-05	composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo
BRPI1011453A2 (pt)	2016-03-15	formulacao, forma de dosagem de um medicamento, e, sal de hemipamoato de asenapina
BR112012003280A2 (pt)	2017-05-23	composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
CL2014001861A1 (es)	2014-11-07	Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.